Marex Group’s Apellis Pharmaceuticals APLS Stock Holding History

Marex Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,919	Closed	-$238K	–	1134
2026 Q1	$238K	Sell	5,919 -17,081	-74%	-$368K	﹤0.01%	850
2025 Q4	$578K	Buy	+23,000	New	+$540K	﹤0.01%	520

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marex Group's APLS Position: Q2 2026 in Review

Marex Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5,919 shares — an estimated $238K sold.

Marex Group first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $578K in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Marex Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marex Group sold 5,919 Apellis Pharmaceuticals shares in Q2 2026, an estimated $238K.
Marex Group first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Marex Group's Apellis Pharmaceuticals position peaked at $578K in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.